This calculator is provided for informational and educational purposes only. It is not intended to replace professional medical advice, diagnosis, or treatment. Always consult with a qualified healthcare professional before making any medical decisions. The results from this calculator should be used as a reference guide only and not as the sole basis for clinical decisions.
Bronchiectasis Severity Index (BSI) Calculator
Calculate the Bronchiectasis Severity Index (BSI) score across 8 validated clinical domains — age, BMI, FEV1% predicted, prior hospitalisation, exacerbation frequency, MRC dyspnoea grade, Pseudomonas aeruginosa colonisation, and other organism colonisation. Get instant BSI severity classification (mild, moderate, or severe), 4-year mortality risk, annual hospitalisation risk estimate, and evidence-based management recommendations aligned with ERS and BTS bronchiectasis guidelines.
- Annual specialist review (primary or secondary care)
- Regular airway clearance physiotherapy
- Influenza and pneumococcal vaccination
- Optimise management of underlying aetiology
This calculator is provided for informational and educational purposes only. It is not intended to replace professional medical advice, diagnosis, or treatment. Always consult with a qualified healthcare professional before making any medical decisions. The results from this calculator should be used as a reference guide only and not as the sole basis for clinical decisions.
About This Bronchiectasis Severity Index (BSI) Calculator
This free online Bronchiectasis Severity Index (BSI) calculator is designed for respiratory healthcare professionals, specialist nurses, and clinicians managing adults with non-cystic fibrosis bronchiectasis (NCFB). The tool enables rapid bedside or outpatient calculation of the BSI score across all eight validated clinical domains — producing immediate severity classification, outcome risk estimates, and management guidance without manual scoring tables or reference lookups.
The calculator implements the BSI as originally described by Chalmers JD and colleagues in the American Journal of Respiratory and Critical Care Medicine (2014), validated across UK, Belgian, and Italian patient cohorts. Each of the eight clinical parameters — patient age, body mass index, FEV1 percent predicted, prior bronchiectasis hospitalisation history, annual exacerbation frequency, Modified MRC Dyspnoea Scale grade, Pseudomonas aeruginosa airway colonisation status, and other pathogenic organism colonisation — contributes weighted points summing to the total BSI score. The scoring is displayed on an interactive risk ladder, gradient severity zone bar, and per-domain breakdown chart aligned with European Respiratory Society (ERS) and British Thoracic Society (BTS) bronchiectasis guidelines.
The risk ladder visualization shows where the patient’s total BSI score sits across 12 colour-coded severity rungs progressing from green (mild, 0-4) through amber (moderate, 5-8) to red (severe, 9+). The gradient zone bar provides an at-a-glance position indicator across the full severity spectrum, while the domain breakdown chart identifies which clinical parameters are driving the overall score — highlighting priority areas for management optimisation. All results are accompanied by evidence-based management recommendations, 4-year mortality estimates, and annual hospitalisation risk ranges drawn from published BSI validation cohort data.
Bronchiectasis Severity Index (BSI) Calculator: A Complete Guide to Assessing Disease Severity and Predicting Clinical Outcomes
Bronchiectasis is a chronic, progressive respiratory condition characterised by permanent abnormal widening and scarring of the bronchial airways, leading to impaired mucus clearance, recurrent infections, and progressive lung function decline. Accurate severity assessment is critical for guiding treatment decisions, predicting outcomes, and stratifying patients for appropriate follow-up and intervention.
The Bronchiectasis Severity Index (BSI) is a validated, multidimensional scoring tool developed to predict clinical outcomes in adults with bronchiectasis, including hospitalisation risk, exacerbation frequency, and mortality. Unlike single-parameter assessments, the BSI integrates clinical, microbiological, radiological, and functional variables into a composite score that reflects the full burden of disease across multiple dimensions.
This guide provides a comprehensive overview of the BSI, its component variables, calculation methodology, clinical interpretation, and practical application in managing patients with bronchiectasis across diverse healthcare settings worldwide.
The Eight Domains of the Bronchiectasis Severity Index
The BSI was developed by Chalmers and colleagues through multivariate analysis of clinical variables associated with hospital admission and mortality in bronchiectasis cohorts from the United Kingdom and Europe. The scoring system encompasses eight distinct clinical domains, each contributing weighted points that reflect their relative importance in predicting outcomes.
The eight domains and their scoring are:
1. Age: Points are assigned based on age group – under 50 years (0 points), 50-69 years (2 points), 70-79 years (4 points), and 80 years or older (6 points). Older age independently predicts worse outcomes in bronchiectasis due to reduced physiological reserve, greater comorbidity burden, and impaired immune response.
2. Body Mass Index (BMI): BMI below 18.5 kg/m² scores 2 points, reflecting the association between undernutrition, sarcopenia, and adverse respiratory outcomes. Normal or overweight BMI scores 0 points.
3. Forced Expiratory Volume in 1 second (FEV1% predicted): Greater airflow limitation scores higher – greater than 80% scores 0 points, 50-80% scores 1 point, 30-49% scores 2 points, and less than 30% predicted scores 3 points. FEV1 is the primary spirometric indicator of airflow obstruction and lung function impairment.
4. Prior Hospital Admissions for Exacerbations: Two or more hospital admissions in the past 2 years scores 5 points; fewer than 2 admissions scores 0 points. Prior hospitalisation is one of the strongest predictors of future adverse outcomes.
5. Exacerbation Frequency: Three or more exacerbations in the past year scores 2 points; fewer than 3 scores 0 points. Frequent exacerbations drive disease progression, accelerate lung function decline, and impair quality of life.
6. Modified Medical Research Council (MRC) Dyspnoea Scale: Dyspnoea grade 4 or 5 (most severe breathlessness) scores 3 points, grades 2-3 score 1 point, and grades 0-1 score 0 points. Breathlessness is a key patient-reported determinant of functional capacity and disease impact.
7. Pseudomonas aeruginosa Colonisation: Chronic colonisation with Pseudomonas aeruginosa scores 3 points. This pathogen is associated with accelerated lung function decline, increased exacerbation frequency, greater antibiotic resistance challenges, and significantly worse prognosis.
8. Colonisation with Other Organisms: Isolation of other potentially pathogenic microorganisms (e.g., Staphylococcus aureus, Haemophilus influenzae, Enterobacteriaceae) scores 1 point.
Development and Validation of the BSI
The BSI was developed by Chalmers JD and colleagues and published in the American Journal of Respiratory and Critical Care Medicine in 2014. The derivation cohort comprised 608 patients from Dundee, Scotland, with independent validation in three external cohorts from Belgium (n=253), Italy (n=119), and a mixed UK cohort (n=126).
The study demonstrated that the BSI was significantly superior to existing severity tools, including the FACED score, in predicting hospitalisation due to bronchiectasis exacerbation. The area under the receiver operating characteristic (ROC) curve for predicting hospital admission was 0.88 in the derivation cohort, with consistent performance across validation cohorts.
Subsequent international validation studies have confirmed BSI performance across North American, European, Asian, Australian, and South American populations, though some studies suggest population-specific recalibration may improve predictive accuracy in certain ethnic groups, particularly those with lower baseline rates of Pseudomonas colonisation or differing exacerbation patterns.
The FACED Score: A Complementary Severity Tool
The FACED score is an alternative bronchiectasis severity score developed by Martinez-Garcia and colleagues, encompassing FEV1 (F), Age (A), Chronic colonisation (C), Extension of bronchiectasis (E), and Dyspnoea (D). While primarily validated for predicting 5-year mortality, FACED has lower sensitivity for predicting hospitalisation and exacerbations compared to the BSI.
The E-FACED score is an extended version incorporating prior exacerbation history, providing improved prediction of exacerbations alongside mortality. Current clinical guidelines from the European Respiratory Society (ERS) and the British Thoracic Society (BTS) recommend the BSI as the preferred multidimensional severity assessment tool, particularly when hospitalisation risk and treatment planning are the primary outcomes of interest.
Chronic Pseudomonas aeruginosa airway infection is one of the highest-weighted variables in the BSI, contributing 3 points – equivalent to the maximum dyspnoea score or severe airflow limitation. This reflects robust evidence that Pseudomonas colonisation independently predicts accelerated lung function decline, increased exacerbation rates, higher healthcare utilisation, and elevated mortality risk in bronchiectasis patients.
Clinical Application of the BSI in Bronchiectasis Management
International bronchiectasis guidelines, including those from the European Respiratory Society (ERS 2017), the British Thoracic Society (BTS 2019), and the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC), recommend using the BSI to guide several key clinical decisions:
Treatment escalation: Patients with severe BSI (9+) typically require consideration of long-term antibiotic prophylaxis (inhaled antibiotics or oral macrolides), aggressive airway clearance physiotherapy, and specialist bronchiectasis clinic review. The BSI can help prioritise patients for early intervention before irreversible disease progression occurs.
Follow-up frequency: Mild BSI patients may be safely managed in primary care or general respiratory clinics with annual review, while moderate and severe patients warrant more frequent specialist assessment – typically every 3-6 months for severe disease.
Inclusion in clinical trials: The BSI is increasingly used as an eligibility and stratification criterion in bronchiectasis clinical trials, enabling better matching of treatment intensity to disease severity and ensuring meaningful subgroup analyses.
Monitoring disease progression: Serial BSI assessment can identify patients experiencing clinical deterioration and prompt earlier treatment adjustments, though longitudinal BSI tracking is less well validated than its cross-sectional predictive performance.
Modified MRC Dyspnoea Scale Reference
The Modified MRC Dyspnoea Scale is a five-grade ordinal scale assessing functional breathlessness limitation:
Grade 0: No breathlessness except during strenuous exercise. Grade 1: Breathlessness when hurrying on level ground or walking up a slight hill. Grade 2: Walks slower than most people on level ground due to breathlessness, or has to stop for breath when walking at own pace. Grade 3: Stops for breath after walking approximately 100 metres or after a few minutes on level ground. Grade 4: Too breathless to leave the house, or breathless when dressing or undressing.
In the BSI scoring, grades 4 and 5 (the most severe dyspnoea) are grouped together as the highest-scoring category (3 points), given their association with severe functional limitation and high healthcare burden.
Microbiological Assessment in BSI Scoring
Accurate microbiological characterisation is essential for correct BSI calculation. Pseudomonas aeruginosa colonisation is defined as isolation of the organism from sputum on two or more occasions at least 3 months apart, or from a single bronchoalveolar lavage sample. Patients with intermittent Pseudomonas isolation (not meeting chronic colonisation criteria) may not score the full 3 points in some interpretations, though clinical practice varies.
Other potentially pathogenic organisms scoring 1 point include Haemophilus influenzae, Streptococcus pneumoniae, Staphylococcus aureus (including MRSA), Moraxella catarrhalis, members of the Enterobacteriaceae family, and other gram-negative organisms. Non-tuberculous mycobacteria (NTM) are not specifically categorised within the standard BSI framework but are associated with disease complexity warranting specialist input.
Patients with moderate-severe BSI (5+) and frequent exacerbations (3+ per year) represent a high-priority group for prophylactic interventions. Long-term macrolide therapy (azithromycin or erythromycin) has demonstrated significant exacerbation reduction in randomised controlled trials. Inhaled antibiotic therapy targeting Pseudomonas aeruginosa (inhaled tobramycin, colistin, aztreonam) is recommended for patients with chronic Pseudomonas colonisation meeting severity thresholds. The BSI provides a structured basis for identifying patients most likely to benefit from these interventions.
FEV1 Measurement and Interpretation
FEV1% predicted is the ratio of a patient’s measured FEV1 to the reference FEV1 for their demographic characteristics (age, sex, height, ethnicity), expressed as a percentage. Reference values should be derived from population-specific normative equations – commonly the Global Lung Function Initiative (GLI-2012) equations are recommended for their comprehensive ethnic and age coverage. Most modern spirometers automatically calculate FEV1% predicted using built-in reference equations.
Spirometry should be performed according to American Thoracic Society (ATS) / European Respiratory Society (ERS) technical standards, including pre-bronchodilator or post-bronchodilator measurements (post-bronchodilator values are preferred for severity assessment as they reflect maximal achievable lung function). Patients should be clinically stable (not within 4 weeks of an acute exacerbation) when spirometry is performed for BSI calculation.
Radiological Extent and BSI Limitations
Notably, the BSI does not incorporate radiological extent of bronchiectasis (the number of lobes or segments involved on CT scan), in contrast to the FACED score. This was a deliberate decision by the BSI developers, reflecting that CT availability and reporting standards vary considerably across healthcare systems globally, and that adding radiological variables did not significantly improve outcome prediction over the clinical variables included.
This makes the BSI more universally applicable in settings where CT reporting of bronchiectasis extent is inconsistent or unavailable. However, CT imaging remains essential for diagnosing bronchiectasis and characterising disease morphology, aetiology, and distribution – even if CT extent is not a BSI component.
Global Application and Population Considerations
The BSI has been validated across diverse international populations including European (Belgian, Italian, Spanish), Asian (Chinese, Korean, Japanese), and South American cohorts. While overall predictive performance has been broadly consistent, some regional differences warrant consideration:
In East Asian populations, baseline Pseudomonas aeruginosa colonisation rates are lower than in European cohorts, which may result in systematically lower BSI scores despite comparable disease burden as assessed by other parameters. Some investigators have proposed Pseudomonas-adjusted BSI thresholds for populations with low baseline Pseudomonas prevalence.
Non-cystic fibrosis bronchiectasis aetiologies vary substantially by region. Post-infectious bronchiectasis (particularly post-tuberculosis) predominates in many developing-world settings, while idiopathic, primary ciliary dyskinesia-related, and immune deficiency-related bronchiectasis are more common in high-income countries. These aetiological differences may influence natural disease history independent of BSI-predicted outcomes.
The BSI was explicitly developed as an outcome prediction tool, not a treatment selection algorithm. Whilst severity categorisation can inform decisions about follow-up frequency, specialist referral, and prophylactic therapy eligibility, treatment decisions should integrate individual patient factors, patient preferences, comorbidities, contraindications, and local guideline recommendations. The BSI complements but does not replace comprehensive clinical evaluation by experienced respiratory specialists.
BSI in Research and Quality Improvement
The BSI is widely used as both an inclusion criterion and a stratification variable in international bronchiectasis clinical trials, including pivotal studies of inhaled antibiotics, mucolytics, and anti-inflammatory agents. Its use as a stratification factor helps ensure balanced randomisation of patients by disease severity and enables meaningful subgroup analyses of treatment effects by severity category.
The European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) registry – the world’s largest bronchiectasis disease registry – collects BSI data on all enrolled patients, enabling real-world audit of BSI performance and treatment patterns across participating countries. EMBARC data have contributed substantially to understanding BSI behaviour in routine clinical practice settings outside of specialist research centres.
Practical Considerations When Calculating BSI
Several practical points merit consideration when calculating the BSI in clinical practice: Hospitalisation data should be specifically for bronchiectasis exacerbation-related admissions (not unrelated admissions). Exacerbation counts should refer to treated exacerbation episodes in the past 12 months – a bronchiectasis exacerbation is defined by acute deterioration with at least 3 of the following symptoms: cough, sputum volume/purulence change, breathlessness/exercise tolerance change, fatigue/malaise, haemoptysis, with or without fever.
Microbiological data should ideally be from sputum samples collected during clinical stability, not during acute exacerbation (which may show transient changes). Patients should be assessed at a clinically stable baseline for accurate FEV1 and MRC dyspnoea scoring. The BSI should be recalculated when significant clinical changes occur (major exacerbation, new Pseudomonas colonisation, new hospitalisation) to ensure severity categorisation reflects current disease status.
Comparing BSI, FACED, and E-FACED Scores
Three multidimensional severity scores are currently used in bronchiectasis research and clinical practice:
The BSI outperforms FACED and E-FACED for predicting hospitalisation and all-cause mortality in most validation studies. E-FACED improves upon FACED for exacerbation prediction by incorporating exacerbation history. FACED is simpler (5 variables vs BSI’s 8) and may be preferred when complete microbiological data are unavailable. Current ERS and BTS guidelines preferentially recommend the BSI for comprehensive severity assessment, while acknowledging E-FACED as an acceptable alternative particularly when CT radiological extent data are available.
Emerging Biomarkers and Future BSI Development
Ongoing research is evaluating whether incorporating additional biomarkers could further improve BSI predictive performance. Candidate biomarkers include serum inflammatory markers (CRP, fibrinogen, neutrophil-to-lymphocyte ratio), sputum inflammatory mediators, microbiome diversity indices, and functional imaging parameters (CT air trapping, ventilation heterogeneity). Artificial intelligence approaches to CT image analysis may eventually enable automated scoring of CT-based variables for integration into future severity scores.
The development of disease-specific patient-reported outcome measures (PROMs) for bronchiectasis, including the Quality of Life-Bronchiectasis (QOL-B) questionnaire and the Bronchiectasis Health Questionnaire (BHQ), has raised interest in whether patient-reported severity dimensions should be integrated into future iterations of multidimensional scoring tools.
All patients with newly diagnosed bronchiectasis warrant specialist respiratory review for diagnostic workup, aetiology investigation, and management planning. Ongoing specialist care is particularly important for patients with BSI score 5+ (moderate-severe), frequent exacerbations (3+ per year), Pseudomonas aeruginosa colonisation, suspected non-tuberculous mycobacterial co-infection, haemoptysis, rapidly progressive disease, or unusual or complex underlying aetiology. Multidisciplinary team (MDT) input from respiratory physiotherapy, microbiology, and in selected cases immunology or infectious diseases, optimises outcomes for complex patients.
Frequently Asked Questions
Conclusion
The Bronchiectasis Severity Index is a rigorously validated, multidimensional clinical tool that provides structured, evidence-based assessment of disease severity and outcome risk in adults with non-cystic fibrosis bronchiectasis. By integrating eight clinical domains – spanning demographics, lung function, microbiological status, symptom burden, and prior healthcare utilisation – the BSI captures the complex, multifactorial nature of bronchiectasis and enables clinically meaningful severity stratification.
Routine BSI assessment, ideally at initial diagnosis and annually thereafter, supports more structured, evidence-based bronchiectasis management – from determining follow-up frequency and specialist referral thresholds to guiding decisions about prophylactic antibiotic strategies and clinical trial eligibility. As the global evidence base for bronchiectasis management continues to expand, the BSI remains the most widely recommended and internationally validated severity tool for adult bronchiectasis practice.
This calculator provides an educational tool for healthcare professionals to calculate and interpret BSI scores at the point of care. All clinical decisions should integrate individual patient factors and be made in consultation with respiratory specialists experienced in bronchiectasis management.